Changing the Treatment Paradigm in Cancer and Fibrotic Disease

learn more >

About Us
About Us

BLR Bio is a privately held biotechnology company committed to the discovery and development of transformational biologics and diagnostics for the treatment of Cancer and a broad spectrum of serious Fibrotic Diseases.

The majority of deaths in the developed world are due to fibroproliferative disease. It is now recognized that the pathways to fibrosis are not greatly different than those responsible for the formation of solid tumors.

more about us »

Our Technology
Our Technology

The CCN family of matricelluar signaling proteins has emerged as a unique and highly promising target for therapies in cancer and fibrotic diseases. Using the body's inherent defense and healing systems, we have created biologic-based therapies employed to activate key cellular proteins and/or block specific receptors addressing the underlying biology of these related diseases.

more about our technology »

Partnering Opportunities
Partnering Opportunities

BLR Bio has a platform of assets targeted at specific diseases including cancer, fibrosis, and scarring. Our capabilities span drug discovery and early development stages to Phase 3 clinical trials. We anticipate that our product candidates will be partnered with pharmaceutical or biotechnology companies for advanced development and marketing. We endeavor to retain a participating role applying our development and commercialization capabilities.

see opportunities »

Latest Video

Latest News

May 2016
"Dr. Bruce Riser, CEO of BLR Bio, was an invited speaker on Peptide Discovery, Preclinical and Clinical presented at the TIDES Oligonucleotide and Peptide Therapeutics Conference, at Long Beach. See selected pre-interview."

April 2016
"BLR Bio was selected as one of the top 50 emerging biotechnology companies to present at the MedCity INVEST, Health Tech Showcase in Chicago April 10-12."

see news archives »


April 2016
Balanced Regulation of the CCN Family of Matricellular Proteins: A Novel Approach to the Prevention and Treatment of Fibrosis and Cancer.
Journal of Cell Communication and Signaling 9.4 (2015): 327–339.
PMC. Web. 28 Apr. 2016.

more publications »